Social Determinants of Health and their Impact on COVID-19

Immunological and Autoimmune Disorders

A Royal Disease: Hemophilia

A Royal Disease: Hemophilia  During the 19th-century British monarch's son Leopold, Duke of Albany slipped and died of blood loss. Not only once, but Queen Victoria’s grandsons died at a compa...

Mar 08, 2021

recent-pharma-biotech-news-updates-happenings-for-beam-grail-quest-diagnostics
Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Beam adds to drug delivery stable with USD 120 Million GuideTx buy Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. Beam announced that it paid USD 120 million upfront to acq...

Find More
recent-pharma-biotech-news-updates-for-verily-janssen-avrobio
Verily – Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis

Verily collaborates with Janssen to launch COVID-19 immune response study Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes.  The study will be launche...

Find More
recent-pharma-biotech-happenings-for-bms-prothena-canon-medical-immunovant
Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs

Plaque psoriasis drug outshines the competition in phase III trial Bristol Myers Squibb’s psoriasis drug, the TYK2 inhibitor outshone placebo and Amgen’s Otezla in a second phase 3 study, setting discussions with regulators. The study, known as POETYK PSO-2, trialled the drug, deucravacitinib, against placebo...

Find More

More Views & Analysis

Horizon, Viela Deal; Concert Schizophrenia Drug Flop; Gilead, Gritstone Deal
Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone

Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the...

Find More

Hemophagocytic Lymphohistiocytosis Treatment Market
A Bleak Pipeline and Lack of Approved Treatment Clouds the Hemophagocytic Lymphohistiocytosis Market Size Growth

Having a strong immune system, flourished with properly working immune cells is the ultimate key to surviving a healthy life. However, what if a person is in possession of overactive immune cells? It leads to improper functioning of the immune system, confusing internal organs as foreign invaders thus attacking the...

Find More

Thrombocytopenia drugs market | Drug-Induced Thrombocytopenia
Thrombocytopenia Drugs Market: What Newer Agents Are Expected To Enter The Market?

The launch of a novel drug in the market is not less than a celebration in the pharmaceutical and healthcare market; however, it also brings the real challenge of sustenance in the market. Similar is the picture of the Thrombocytopenia Drugs Market. Thrombocytopenia pipeline possesses potential drugs in mid-stage d...

Find More

recent-pharma-biotech-news-updates-gilead-vir-teladoc-tessera-dexcom-verve
Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate

Gilead and Vir Biotechnology Establish Clinical Collaboration  Gilead Sciences, Inc. and Vir Biotechnology, Inc. announced that the companies have entered into a clinical collaboration to assess novel therapeutic combination strategies to develop a functional remedy for chronic hepatitis B virus (HBV). T...

Find More

Hepatitis D Market | Hepatitis D Treatment Market | HDV Market
Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook?

Recent years have been experiencing a dramatic increase in the number of Hepatitis D cases. It is spreading at a rapid rate. DelveInsight estimated that the total diagnosed Hepatitis D prevalence was reported to be 204,976 in 2017 in the 7MM (the US, EU5 (the UK, Germany, Spain, France, and Italy) and Japan). Furth...

Find More

Chronic Hepatitis B Market
Search for the Cure Continues in the Chronic Hepatitis B Treatment Market

Hepatitis B virus (HBV) infection is the 10th leading cause of death worldwide. With 2 billion people infected all over, HBV infection is a reason behind 500 000 to 1.2 million deaths per year. Hepatitis B is a lethal infection and has been a major global problem for years. If it lasts for over 6 months, it is term...

Find More

IPSCs have enormous applications in the field of regenerative medicine, disease modelling, and drug .....

Find More

An inflammatory disease of large intestine, Ulcerative Colitis (UC), is approached with therapies th.....

Find More

Scleroderma is a chronic disease that affects the skin, the connective tissue that supports and hold.....

Find More

In the present scenario, the 3-D printing and bioprinting technology in the medical devices industry.....

Find More

Well, MDS being one of the rare blood cancers, has been into the limelight of researchers since a de.....

Find More

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare form of neoplasm, generally .....

Find More